# Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults

> **NCT05500898** · PHASE1 · UNKNOWN · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 53 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DWP16001
- **DRUG:** DWC202204+DWC202205
- **DRUG:** DWP16001+DWC202204+DWC202205

## Key facts

- **NCT ID:** NCT05500898
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-26
- **Primary completion:** 2022-10-31
- **Final completion:** 2023-02-28
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2022-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05500898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05500898, "Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05500898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*